Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The recent launch event of the Experimental Medicine Industry Partnership was an exciting collaboration between industry representatives and researchers from the University of Oxford. During the event, a series of workshops were held to discuss opportunities, challenges, and future directions for the application of experimental medicine in psychiatric drug development.

Business Unity and connection partnership as ropes shaped as a circle in a group of diverse strings connected together shaped as a support symbol expressing the feeling of teamwork and togetherness.

Dr Susannah Murphy, Department of Psychiatry, University of Oxford, explains:

 

'The Experimental Medicine Industry Partnership (EMIP) is a fantastic opportunity for industry partners and researchers to work together to share expertise and maximise opportunities for developing improved psychiatric treatments. By offering tailored peer review and advice the EMIP will help to rapidly progress new treatments into clinical trials, bringing potential new, life changing treatments a step closer to improving the lives of patients.'

Professor Catherine Harmer, Department of Psychiatry, University of Oxford, said:

 

'It was fascinating to hear pressing questions from an industry perspective and to take part in discussions with other academics. The conversations have spearheaded many collaborations and have inspired us to develop our models in ways that can also work for industry and their requirements. I look forward to continued and future collaborations.'

50 representatives from 15 industry partners and 90 Oxford researchers with expertise in cognitive neuroscience, pharmacology treatment, lifestyle interventions, gut health and precision psychiatry, took part in the AIMday event in July 2021, . 

Read more about this and other topics discussed during the event

For more information about the Experimental Medicine and Industry Partnership (EMIP) 

An Academic Industry Meeting Day (AIMday) is an innovative networking event that allows organisations external to the University of Oxford to set the agenda and gain academic perspective on industry challenges. 

The event was developed through the National Institute for Health Research Oxford Health Biomedical Research Centre (a partnership between the University of Oxford and the Oxford Health NHS Foundation Trust).

Similar stories

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between a core team of Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institute, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.

Researchers awarded Wellcome Innovator Grant to investigate role of brainstem nucleus in human consciousness

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.